European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. USO
8. HOOD
9. DFTX
10. RGNX

Go back to European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
AIMSI Technologies (NASDAQ: AIMT) Delayed: 34.49 --0 (-0%)
Previous Close $34.49    52 Week High $27.31 
Open $7.76    52 Week Low $9.77 
Day High $34.49    P/E N/A 
Day Low $34.49    EPS $0.00 
Volume 42,896